Abstract
The availability of enfuvirtide enables assessment of whether human immunodeficiency virus (HIV) decay can be enhanced by targeting reverse transcriptase, protease, and fusion. We performed a 12-week study of 22 patients randomized to receive ritonavir-boosted saquinavir and efavirenz with (the 3-target arm) or without (the 2-target arm) enfuvirtide. We observed no difference in the mean+/-SD elimination-rate constant for overall decay (0.142+/-0.040 per day and 0.128 +/- 0.033 per day in the 2- and 3-target arms, respectively; P>.1) or for modeled first-phase decay rate (-0.62+/-0.34 per day and -0.51+/-0.16 per day; P>.1). Antiretroviral therapy that inhibits HIV reverse transcriptase and protease exerts potent antiviral effects that might not be augmented by the addition of an HIV fusion inhibitor.
Publication types
-
Randomized Controlled Trial
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, Non-P.H.S.
MeSH terms
-
Alkynes
-
Anti-HIV Agents / administration & dosage
-
Anti-HIV Agents / therapeutic use
-
Benzoxazines
-
Cyclopropanes
-
Drug Therapy, Combination
-
Enfuvirtide
-
Female
-
HIV Envelope Protein gp41 / administration & dosage
-
HIV Envelope Protein gp41 / therapeutic use*
-
HIV Infections / drug therapy*
-
HIV Infections / virology*
-
HIV-1 / drug effects*
-
HIV-1 / physiology
-
Humans
-
Male
-
Oxazines / administration & dosage
-
Oxazines / therapeutic use*
-
Peptide Fragments / administration & dosage
-
Peptide Fragments / therapeutic use*
-
Ritonavir / administration & dosage
-
Ritonavir / therapeutic use*
-
Saquinavir / administration & dosage
-
Saquinavir / therapeutic use*
-
Viral Load
Substances
-
Alkynes
-
Anti-HIV Agents
-
Benzoxazines
-
Cyclopropanes
-
HIV Envelope Protein gp41
-
Oxazines
-
Peptide Fragments
-
Enfuvirtide
-
efavirenz
-
Saquinavir
-
Ritonavir